Cybin (NASDAQ:HELP – Get Free Report) released its quarterly earnings data on Friday. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.74), FiscalAI reports.
Cybin Price Performance
Shares of HELP traded up $0.01 during trading hours on Friday, hitting $8.87. The stock had a trading volume of 976,721 shares, compared to its average volume of 1,441,180. Cybin has a 12 month low of $3.76 and a 12 month high of $15.15. The firm has a market capitalization of $707.91 million, a PE ratio of -2.94 and a beta of 0.64. The stock has a fifty day moving average price of $11.24 and a 200 day moving average price of $7.81.
Insider Transactions at Cybin
In other Cybin news, CEO Michael Halstead bought 100,000 shares of the business’s stock in a transaction that occurred on Monday, September 21st. The stock was bought at an average cost of $13.47 per share, for a total transaction of $1,347,000.00. Following the completion of the transaction, the chief executive officer owned 168,568 shares of the company’s stock, valued at $2,270,610.96. This represents a 145.84% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Paul Glavine purchased 100,000 shares of the company’s stock in a transaction dated Tuesday, September 8th. The shares were acquired at an average price of $12.47 per share, for a total transaction of $1,247,000.00. Following the purchase, the insider directly owned 4,271,252 shares in the company, valued at approximately $53,262,512.44. The trade was a 2.40% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 688,000 shares of company stock worth $8,422,830 in the last three months. 15.00% of the stock is owned by insiders.
Institutional Investors Weigh In On Cybin
Several hedge funds and other institutional investors have recently modified their holdings of HELP. AXQ Capital LP bought a new position in Cybin in the 2nd quarter worth $75,000. Farther Finance Advisors LLC grew its holdings in Cybin by 927.4% during the third quarter. Farther Finance Advisors LLC now owns 22,818 shares of the company’s stock valued at $280,000 after purchasing an additional 20,597 shares during the period. State Street Corp purchased a new stake in Cybin in the third quarter worth about $363,000. Pale Fire Capital SE purchased a new stake in Cybin in the second quarter worth about $1,015,000. Finally, WealthPlan Investment Management LLC purchased a new stake in Cybin in the third quarter worth about $1,272,000. 17.94% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several research firms have issued reports on HELP. Wall Street Zen cut shares of Cybin from a “sell” rating to a “strong sell” rating in a research note on Saturday, November 7th. Barclays started coverage on shares of Cybin in a research note on Friday, September 18th. They issued an “overweight” rating and a $35.00 price target for the company. Wells Fargo & Company lifted their price target on shares of Cybin from $16.00 to $22.00 and gave the stock an “overweight” rating in a research note on Thursday, October 22nd. Finally, TD Cowen boosted their price objective on shares of Cybin from $8.00 to $62.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Six research analysts have rated the stock with a Buy rating. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $47.33.
Check Out Our Latest Report on HELP
Cybin Company Profile
Cybin, which changed its name to Helus Pharma, is a clinical-stage biopharmaceutical company developing psychedelic-based treatments for mental health conditions. Its research focuses on designing and evaluating investigational compounds intended to address conditions including depression and anxiety disorders. The company’s pipeline has included CYB003, a deuterated psilocin analog being studied for major depressive disorder, and CYB004, an investigational DMT-based treatment studied for generalized anxiety disorder.
Read More
- Five stocks we like better than Cybin
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.
